Technical Analysis for XCUR - Exicure, Inc.

Grade Last Price % Change Price Change
B 18.38 69.24% 7.52
XCUR closed up 69.24 percent on Friday, November 22, 2024, on 2.66 times normal volume. The bulls were able to push the stock to a new 52-week high.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Parabolic Rise Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 11 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
2x Volume Pace about 17 hours ago
1.5x Volume Pace about 17 hours ago
3x Volume Pace about 17 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Exicure, Inc. Description

Exicure, Inc., a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005; and license and development agreement DERMELIX, LLC, d/b/a Dermelix Biotherapeutics to research, develop, and commercialize Exicure's technology for the treatment of Netherton Syndrome and for five additional rare skin indications. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Acid Psoriasis Netherton Syndrome Messenger RNA Oncology Applications

Is XCUR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.62
52 Week Low 1.44
Average Volume 1,605,868
200-Day Moving Average 2.71
50-Day Moving Average 3.60
20-Day Moving Average 4.64
10-Day Moving Average 6.52
Average True Range 1.91
RSI (14) 92.16
ADX 53.49
+DI 69.11
-DI 2.05
Chandelier Exit (Long, 3 ATRs) 13.89
Chandelier Exit (Short, 3 ATRs) 8.06
Upper Bollinger Bands 12.66
Lower Bollinger Band -3.38
Percent B (%b) 1.36
BandWidth 345.87
MACD Line 2.30
MACD Signal Line 0.87
MACD Histogram 1.4264
Fundamentals Value
Market Cap 158.96 Million
Num Shares 8.65 Million
EPS 1.77
Price-to-Earnings (P/E) Ratio 10.38
Price-to-Sales 0.21
Price-to-Book 0.53
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.85
Resistance 3 (R3) 28.10 23.86 27.10
Resistance 2 (R2) 23.86 21.19 24.23 26.52
Resistance 1 (R1) 21.12 19.55 22.49 21.87 25.94
Pivot Point 16.88 16.88 17.57 17.26 16.88
Support 1 (S1) 14.14 14.21 15.51 14.89 10.82
Support 2 (S2) 9.90 12.57 10.28 10.24
Support 3 (S3) 7.16 9.90 9.66
Support 4 (S4) 7.91